Keyword: Medicare

Amgen declared the launch of migraine drug Aimovig an unqualified success, but analysts weren't quite ready to buy in to the euphoria.

Pharma has come under political pressure in Washington, D.C., and lobby spending figures indicate the industry is taking the threat seriously.

After a CMS rule change in August, UnitedHealthcare is introducing step therapy in Medicare Advantage plans to favor biosimilars over certain brands.

Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.

PhRMA called new donut-hole drug discounts a "massive bailout" for payers, but the insurance lobby says pharma's arguments are "ridiculous."

Pharma suffered a blow in the Senate's budget deal, but how much will drugmakers really lose? Not a lot, on average, but some will take a bigger hit.

Pharma stands to prevail again in Washington, D.C., if a new Part D rule proposal from the Centers for Medicare & Medicaid Services makes its way into law.

A new study in JAMA has put the focus back on the price of Mallinckrodt's controversial med, H.P. Acthar gel.

Gilead hit with revived lawsuit claiming it sourced a key HIV drug ingredient from an unapproved Chinese manufacturer.

One prominent pharma CEO figures overhauling healthcare won't take a few weeks of work. Think years—even decades.